Relative recirculation: A fast, model-free surrogate for the measurement of blood-brain barrier permeability and the prediction of hemorrhagic transformation in acute ischemic stroke

Investigative Radiology

Volumn 44, Issue 10, 2009, Pages 662-668

  Wu, Shengping ^a   Thornhill, Rebecca E ^a,b   Chen, Shuo ^b   Rammo, Wael ^b   Mikulis, David J ^c   Kassner, Andrea ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Acute stroke; Dynamic susceptibility contrast; Hemorrhagic transformation; MRI; Permeability

Indexed keywords

ALTEPLASE; GADODIAMIDE;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HEMISPHERE; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SYMPTOM; THREE DIMENSIONAL IMAGING;

EID: 70349664179     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181ae9c40     Document Type: Article

References (35)

1. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109-2118.
2. Hamann GF, del Zoppo GJ, von Kummer R. Hemorrhagic transformation of cerebral infarction: possible mechanisms. Thromb Haemost. 1999;82(suppl 1): 92-94.
3. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
4. Kent DM, Ruthazer R, Selker HP. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? Stroke. 2003;34:464-467.
5. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
6. Latour LL, Kang DW, Ezzeddine MA, et al. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol. 2004;56:468-477.
7. Kassner A, Roberts T, Taylor K, et al. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. Am J Neuroradiol. 2005; 26:2213-2217.
8. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009;44:226-233
9. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
10. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65-75.
11. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol. 2007;42:139-145.
12. FDA Center for Drug Evaluation and Research. Gadolinium-containing Contrast Agents for Magnetic Resonance Imaging (MRI): Omniscan, Opti-MARK, Magnevist, ProHance, and MultiHance [U.S. Food and Drug Administration/Center for Drug Evaluation and Research]. June 8, 2006. Available at http://www.fda.gov/cder/drug/advisory/gadolinium-agents.htm. Accessed April 23, 2009.
13. Kassner A, Annesley DJ, Zhu XP, et al. Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: a possible marker of vascular tortuosity. JMagn Reson Imaging. 2000;11:103-113.
14. Lupo JM, Cha S, Chang SM, et al. Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. Am J Neuroradiol. 2005;26:1446-1454.
15. Bang OY, Buck BH, Saver JL, et al. Prediction of hemorrhagic transformation after recanalization therapy using T2*-permeability magnetic resonance imaging. Ann Neurol. 2007;62:170-176.
16. Johnson G, Wetzel SG, Cha S, et al. Measuring blood volume and vascular transfer constant from dynamic, T*2-weighted contrast-enhanced MRI. Magn Reson Med. 2004;51:961-968.
17. Kidwell CS, Wintermark M. Imaging of intracranial hemorrhage. Lancet Neurol. 2008;7:256-267.
18. Roberts HC, Roberts TP, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. Am J Neuroradiol. 2000;21:891-899.
19. Rosen BR, Belliveau JW, Vevea JM, et al. Perfusion imaging with NMR contrast agents. Magn Reson Med. 1990;14:249-265.
20. A Language and Environment for Statistical Computing, R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria, 2008. ISBN 3-900051-07-0. Available at: http://www.R-project.org.
21. Hamann GF, Okada Y, Fitridge R, et al. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke. 1995;26:2120-2126.
22. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
23. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab. 1985;5:584-590.
24. Dankbaar JW, Hom J, Schneider T, et al. Dynamic perfusion CT assessment of the blood-brain barrier permeability: first pass versus delayed acquisition. Am J Neuroradiol. 2008;29:1671-1676.
25. Vidarsson L, Liu F, Moran B, et al. Quantitative permeability MRI in acute ischemic stroke: how long do we need to scan? Proc Intl Soc Mag Reson Med. 2008;16:1888.
26. Eveloch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging. 1999;10:254-259.
27. Cheng HL. Investigation and optimization of parameter accuracy in dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2008;28:736-743.
28. Nagaraja TN, Nagesh V, Ewing JR, et al. Step-down infusions of Gd-DTPA yield greater contrast-enhanced magnetic resonance images of BBB damage in acute stroke than bolus injections. Magn Reson Imaging. 2007;25:311-318.
29. Quarles CC, Ward BD, Schmainda KM. Improving the reliability of obtaining tumor hemodynamic parameters in the presence of contrast agent extravasation. Magn Reson Med. 2005;53:1307-1316.
30. Miyati T, Banno T, Mase M, et al. Dual dynamic contrast-enhanced MR imaging. J Magn Reson Imaging. 1997;7:230-235.
31. Quarles CC, Gore JC, Yankeelov TE. Validation of a dual echo DSC-MRI approach that enables the simultaneous measurement of blood flow, blood volume, and Ktrans. Proc Intl Soc Mag Reson Med. 2008;16:635.
32. Jackson A, Kassner A, Annesley-Williams D, et al. Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade. Am J Neuroradiol. 2002;23:7-14.
33. Yepes M, Sandkvist M, Moore EG, et al. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest. 2003;112:1533-1540.
34. Wang XY, Tsuji K, Lee SR, et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke. 2004;35(suppl 1):2726-2730.
35. Burggraf D, Martens HK, Jäger G, et al. Recombinant human tissue plasmin-ogen activator protects the basal lamina in experimental focal cerebral ischemia. Thromb Haemost. 2003;89:1072-1080.